Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...

The FDA has approved Johnson & Johnson’s nipocalimab (Imaavy) for adults and paediatric patients 12 years of age and older with generalized myasthenia gravis (gMG) and anti-acetylcholine ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include myasthenia gravis activities of daily living scale (MG-ADL) and quantitative myasthenia gravis (QMG) ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

said the company’s work around the launch of the prefilled syringe reflects discussions with generalized myasthenia gravis (gMG) patients. “We listened to the voices of patients in the gMG ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It typically leads to symptoms such as muscle weakness, drooping eyelids, ...